IRAG
AZN icon

Investment Research & Advisory Group’s AstraZeneca AZN Stock Holding History

Investment Research & Advisory Group’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2
Closed -$197 – 252
2024
Q4 		$197 Hold
2
– – ﹤0.01% 203
2024
Q3 		$312 Buy
+2
New +$323 ﹤0.01% 201

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Investment Research & Advisory Group's AZN Position: Q1 2025 in Review

Investment Research & Advisory Group sold out of AstraZeneca (AZN) in Q1 2025, closing a stake of 2 shares — an estimated $197 sold.

Investment Research & Advisory Group first reported a position in AZN in Q3 2024 and held it in 2 quarters. The position peaked at $312 in Q3 2024. 1,249 funds tracked by Wall St. Rank hold AZN as of Q1 2025.

  • Investment Research & Advisory Group reported no remaining AstraZeneca position as of Q1 2025 after selling out during the quarter.
  • Investment Research & Advisory Group sold 2 AstraZeneca shares in Q1 2025, an estimated $197.
  • Investment Research & Advisory Group first reported a position in AstraZeneca in Q3 2024 and held it in 2 quarters.
  • Investment Research & Advisory Group's AstraZeneca position peaked at $312 in Q3 2024.
  • 1,249 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2025.

Based on Investment Research & Advisory Group's 13F filing for Q1 2025, filed 21 Apr 2025.